Member of the Board since 2022.
Britt Meelby Jensen is a Danish citizen. She holds a MSc in International Marketing and Management from Copenhagen Business School and has earned an MBA from Solvay Business School (Université Libre de Bruxelles).
Britt has over twenty years of experience from the life science industry, pharma, diagnostics, biotech and medtech. From 2019 to early 2022, Britt Meelby Jensen served as CEO of Atos Medical AB. In connection with selling the company to Coloplast, Britt decided to step down as CEO to continue as an adviser as of March 2022. From 2015 to 2019, Britt Meelby Jensen was President and CEO of Zealand Pharma A/S. During her leadership, the company was listed on Nasdaq in the US. Prior to this, Britt Meelby Jensen served as CEO for Dako A/S in 2013-2014.
Britt Meelby Jensen joined Novo Nordisk A/S in 2002, where she assumed several leadership roles, including the role of Corporate Vice President of Global Marketing, Market Access & Commercial Excellence. Between 2000 and 2002, Britt Meelby Jensen served as Management Consultant with McKinsey & Company.